R. Shorthouse

发表

Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro.

J. Gummert, M. Barten, R. Morris, 2001, Journal of immunological methods.

Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement.

V. Dzau, R. Morris, C. Gregory, 1995, Transplantation.

Rapamycin (Sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells.

R. Morris, C. Gregory, M. Billingham, 1995, Transplantation proceedings.

Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts.

G. Berry, R. Morris, X. Huang, 2000, Transplantation.

Chronic rejection: The result of uncontrolled remodelling of graft tissue by recipient mesenchymal cells? Data from two rodent models and the effects of immunosupressive therapies

R. Morris, T. Brazelton, B. Adams, 1999, Inflammation Research.

Enhancement of obliterative airway disease in rat tracheal allografts infected with recombinant rat cytomegalovirus.

G. Berry, H. Reichenspurner, M. Nitschke, 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Obliterative airway disease after heterotopic tracheal xenotransplantation: pathogenesis and prevention using new immunosuppressive agents.

G. Berry, H. Reichenspurner, M. Nitschke, 1997, Transplantation.

Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo.

R. Morris, X. Huang, R. Braun-Dullaeus, 1997, Transplantation Proceedings.

Studies in experimental models of chronic rejection: use of rapamycin (sirolimus) and isoxazole derivatives (leflunomide and its analogue) for the suppression of graft vascular disease and obliterative bronchiolitis.

G. Berry, R. Morris, C. Gregory, 1995, Transplantation proceedings.

Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion.

E. Nakakura, G. Blank, R. Morris, 1993, Transplantation.

Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo.

P. Huie, V. Dzau, R. Morris, 1993, Transplantation proceedings.

A novel inhibitor of nuclear factor-kappa B and activator protein-1 transcription factors in T cells suppresses host-versus-graft alloreactivity in vivo.

R. Morris, M. Suto, M. Morikawa, 1997, Transplantation proceedings.

Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy.

E. Nakakura, R. Morris, P. Jardieu, 1996, Transplantation.

Effects of the new and highly active immunosuppressant, rapamycin, on lymphoid tissues and cells in vivo.

G. Berry, R. Morris, M. Masek, 1991, Transplantation proceedings.

A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection.

R. Morris, J. Wu, R. Shorthouse, 1990, Transplantation proceedings.

PREPARATION, CHARACTERIZATION, AND PRIMATE TESTING OF MONOCLONAL ANTITHYMOCYTE GLOBULIN

E. Stinson, J. Pennock, C. Bieber, 1981, Transplantation.

Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model.

R. Poston, R. Morris, R. Robbins, 1999, Circulation.

Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury.

P. Huie, R. Morris, J. Wang, 1993, Transplantation proceedings.

Novel assays of multiple lymphocyte functions in whole blood measure: new mechanisms of action of mycophenolate mofetil in vivo.

J. Gummert, R. Morris, T. van Gelder, 2002, Transplant immunology.

A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2.

P. Kao, R. Morris, R. E. Morris, 1996, Transplantation proceedings.

Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation.

R. Morris, H. Silva, R. Shorthouse, 1996, Transplantation proceedings.

Pharmacodynamics of Mycophenolate Mofetil after Heart Transplantation: New Mechanisms of Action and Correlations with Histologic Severity of Graft Rejection

J. Gummert, M. Barten, R. Morris, 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation.

R. Morris, J. Wu, R. Shorthouse, 1990, Transplantation Proceedings.

Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions.

R. Morris, R. E. Morris, J. Wu, 1991, Transplantation proceedings.

Leflunomide abrogates accelerated heart allograft rejection in presensitized rats.

M. Billingham, T. Brazelton, R. Shorthouse, 1997, Transplantation proceedings.

In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis.

R. Morris, M. Löffler, H. Silva, 1997, Transplantation proceedings.

Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury.

R. Morris, X. Huang, B. Zheng, 1995, Transplantation proceedings.

A non-lymphocyte-depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts.

E. Nakakura, G. Blank, R. Morris, 1993, Transplantation proceedings.

Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats.

R. Morris, H. Silva, R. Shorthouse, 1996, Transplantation proceedings.

Immunopharmacology of FK-506.

R. Morris, R. E. Morris, M. Murphy, 1989, Transplantation proceedings.

SP100030 is a novel T-cell-specific transcription factor inhibitor that possesses immunosuppressive activity in vivo.

D. W. Anderson, R. Morris, M. Suto, 1996, Transplantation proceedings.

New approach in drug development: whole blood pharmacodynamic assays reflect biological activities of tacrolimus.

R. Morris, T. van Gelder, C. Dambrin, 2001, Transplantation proceedings.

Enhanced nitric oxide production induced by the administration of L-arginine does not inhibit arterial neointimal formation after overwhelming alloimmune injury.

J. Cooke, R. Morris, C. Gregory, 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.